优化罕见疾病试验:KL1333在成年人线粒体疾病的1a/1b阶段随机研究
Chiara Pizzamiglio1,2, Renae J Stefanetti3,4,5, Robert McFarland3,4,5
1Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology, London WC1N 3BG, UK.
Brain : a journal of neurology
|December 10, 2024
概括
这项研究发现,新型分子KL1333在健康的志愿者和患有初级线粒体疾病的患者中是安全和耐受的,有望改善疲劳和功能.
科学领域:
- 生物化学 生物化学
- 临床药理学 临床药理学
- 罕见疾病 罕见疾病
背景情况:
- 在过去的二十年中,对为罕见疾病开发孤儿药物的兴趣增加.
- 对于罕见疾病的临床试验设计仍然存在重大障碍.
- 主要线粒体疾病影响ATP的产生,影响细胞能量.
研究的目的:
- 评估新型口服分子KL1333.3的安全性和耐受性.
- 探索KL1333的潜力,使NAD+:NADH比率正常化以产生ATP.
- 为了为罕见疾病的后期疗效研究的设计提供信息.
主要方法:
- 在健康志愿者和患有初级线粒体疾病的受试者中进行1a/1b期研究.
- 整合了创新的设计元素:患者参与,适应性设计和探索性目标.
- 评估了安全性,耐受性和新的结果措施,如30岁的坐立测试和疲劳表.
主要成果:
- KL1333显示出安全且耐受性良好的特征.
- 观察到剂量依赖的胃肠道副作用.
- 验证了初级线粒体疾病的新型结果措施,包括疲劳量表和功能测试.
- 数据支持KL1333的疗效,显示疲劳,功能强度和耐力有所改善.
结论:
- 第1期研究对于优化后期疗效试验设计非常有价值.
- KL1333显示了作为治疗原发性线粒体疾病的治疗剂的潜力.
- 创新的试验设计,包括患者的意见,可以克服罕见疾病研究的挑战.
相关概念视频
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K


